The United States Patent and Trademark Office (USPTO) has granted a fundamental patent (US Patent 9,370,431) covering the practice of administering any spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker to Predictive Technology.
“We are pleased to see this latest patent issuance that supports Predictive Technology’s novel approach to diagnosing spinal disorders and syndromes,” says Mike Schramm, Predictive Technology’s director of Intellectual Property. “This issued US patent supports the commercial use of both our diagnostic and next-generation companion treatment products.”
“We are gratified to see this latest patent issuance, which covers the core technology underlying the company’s first available molecular diagnostic test,” says Bradley Robinson, president and chief executive officer of Predictive Technology.
The patent establishes the foundation of intellectual property covering any treatment options (drug, surgery, bracing, etc.) for patients having a specific spine deformity biomarker.